Tumor News and Research

RSS

OncoSec's tumor-destroying, tissue-sparing drug/device system profiled in Medical Device Daily

OncoSec Medical Inc., a therapeutic oncology company developing innovative medical approaches to treat solid tumor cancers with unmet medical needs, announced today the cancer therapy company's tumor-destroying, tissue-sparing drug/device technology was profiled in Medical Device Daily, the news source for the high-tech medical technology industry that is relied on by thousands of industry insiders every business morning.

9 May 2011

Breast cancer cells utilize tissue stem cell EMT for tumor metastasis

Researchers at the University of North Carolina at Chapel Hill School of Medicine, after isolating normal stem cells that form the developing placenta, have given them the same properties of stem cells associated with an aggressive type of breast cancer.

7 May 2011

Study confirms prognostic role of CTC in metastatic breast cancer

French researchers have reported the strongest proof yet that evidence of 'circulating tumor cells' found in samples of a patient's blood is strongly linked to poor outcomes such as a short time to disease progression.

7 May 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2011, the largest and most prestigious gastroenterology meeting, from May 7-10, 2011, at McCormick Place, Chicago, IL.

7 May 2011

Enzon first quarter adjusted loss from continuing operations decreases to $4.2 million

Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2011.

7 May 2011

ImmunoCellular reports updated ICT-107 Phase I trial data in glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme, the most common and aggressive form of brain cancer.

6 May 2011

Study offers means of activating T cells to fight disease without antigenic triggers

For much of the time our T cells-the white blood cells that act as the police of the immune system-are in what immunologists call a "quiescent state," a sort of standby mode. For years, scientists have wondered if quiescence occurred by default or whether T cells need to work at remaining silent.

6 May 2011

DiagnoCure to showcase Previstage GCC Colorectal Cancer Staging Test at ASCRS meeting

DiagnoCure, Inc., a life sciences company commercializing high‐value cancer diagnostic tests and delivering laboratory services, today reported that its PrevistageTM GCC Colorectal Cancer Staging Test will be featured at the annual meeting of the American Society of Colon and Rectal Surgeons to be held in Vancouver, Canada, from May 15 to 17, 2011, with 3,000 expected attendees.

6 May 2011

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Millennium: The Takeda Oncology Company today reported results from three studies in relapsed multiple myeloma. Two of the studies examined the use of VELCADE for Injection; the third study presents clinical data on MLN9708, the first investigational oral proteasome inhibitor.

6 May 2011

Despite expanded Medicare coverage racial disparities continue in colorectal cancer screening

Despite expanded Medicare coverage for colorectal cancer screening tests, lower rates still exist among blacks and Hispanics compared to other ethnic groups, according to research published in Cancer, Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

6 May 2011

Surgery reduces mortality risk of prostate cancer

A Swedish research team partly consisting of researchers from Uppsala University followed a group of prostate cancer patients in the Nordic region for 15 years. The study found, among other things, that surgery reduces the risk that men with prostate cancer (even those with low-risk tumours) will die within 15 years. The results were published today in the New England Journal of Medicine.

6 May 2011

Targeting Aurora A gene could halt rhabdoid tumor growth in children

There are no effective treatments for rhabdoid tumors - aggressive childhood cancers that usually strike children under three years old and affect the brain or kidneys. The disease is extremely rare - fewer than 10 cases are diagnosed each year in the U.S. - but is particularly difficult to treat and almost always fatal.

6 May 2011

First pelvic reconstruction surgery in cancer patient performed at Ohio State's Medical Center

In a rare and medically remarkable operation, a multi-disciplinary team of surgeons at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute removed the left leg, hip and pelvis of a cancer patient, and used the healthy, living bones from his amputated leg to completely rebuild the connection between his spine and remaining right pelvis to support a high-tech prosthetic leg.

6 May 2011

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration approved Afinitor tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin in patients with unresectable, locally advanced or metastatic disease.

6 May 2011

CytRx reports $6.3 million net loss for first quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months ended March 31, 2011, and provided a business update.

5 May 2011

ArQule reports net loss of $1,466,000 for first quarter 2011

ArQule, Inc. today announced its financial results for the first quarter of 2011.

5 May 2011

Researchers identify unexpected triple-negative breast cancer marker

German researchers have identified an unexpected molecular marker that predicts how sensitive hard-to-treat triple-negative breast cancers are to chemotherapy.

5 May 2011

Two breast cancer genomic tests produce broadly similar results for high and low-risk patients

Two multi-gene tests designed to predict the risk of disease progression and response to chemotherapy in breast cancer produce broadly similar results for high- and low-risk patients, but do not always agree in their predictions for those at intermediate risk, a new analysis shows.

5 May 2011

Insight into breast cancer

Measuring the transfer of tiny amounts of energy from one protein to another on breast cancer cells has given scientists a detailed view of molecular interactions that could help predict how breast cancer patients will respond to particular therapies.

5 May 2011

Genome epigenetic analysis reveals new ways to detect and treat breast cancer

The most comprehensive analysis yet of the epigenetic modifications present in breast cancer has revealed potentially important new ways to detect and treat the disease, Belgian researchers have reported.

5 May 2011

Tumor News and Research

OncoSec's tumor-destroying, tissue-sparing drug/device system profiled in Medical Device Daily

Breast cancer cells utilize tissue stem cell EMT for tumor metastasis

Study confirms prognostic role of CTC in metastatic breast cancer

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Enzon first quarter adjusted loss from continuing operations decreases to $4.2 million

ImmunoCellular reports updated ICT-107 Phase I trial data in glioblastoma multiforme

Study offers means of activating T cells to fight disease without antigenic triggers

DiagnoCure to showcase Previstage GCC Colorectal Cancer Staging Test at ASCRS meeting

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Despite expanded Medicare coverage racial disparities continue in colorectal cancer screening

Surgery reduces mortality risk of prostate cancer

Targeting Aurora A gene could halt rhabdoid tumor growth in children

First pelvic reconstruction surgery in cancer patient performed at Ohio State's Medical Center

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

CytRx reports $6.3 million net loss for first quarter 2011

ArQule reports net loss of $1,466,000 for first quarter 2011

Researchers identify unexpected triple-negative breast cancer marker

Two breast cancer genomic tests produce broadly similar results for high and low-risk patients

Insight into breast cancer

Genome epigenetic analysis reveals new ways to detect and treat breast cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News